ARBs and ACEis together in the treatment of hypertension and its complications? current practical recommendations

Bibliography

• Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121:1244-63
   PubMed Web of Science ®Google Scholar
• Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher T. Renal function, the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 2001;38:1782-7
   PubMed Web of Science ®Google Scholar
• Taal MW, Brenner BM. Renal risk scores: progress and prospects. Kidney Int 2008;73:1216-19
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• MacMahon S, Peto R, Cutler J, Prolonged differences in blood pressure: prospective observational Studies corrected for the regression dilution biass. Lancet 1990;335:765-74
   PubMed Web of Science ®Google Scholar
• Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 2007;29:1803-24
   PubMed Web of Science ®Google Scholar
• Wolf-Maier K, Cooper RS, Banegas JR, Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003;289:2363-9
   PubMed Web of Science ®Google Scholar
• Staessen J, Lijnen P, Fagard R, Rise in plasma concentration of aldosterone during long-term angiotensina II suppression. J Endocrinol 1981;91:457-65
   PubMed Web of Science ®Google Scholar
• Gustafsson F, Segura J, Ruilope LM. How should we manage heart failure developing in patients already treated with ACE inhibitors and beta-blockers for hypertension, diabetes or coronary disease. J Hypertension 2010;28:1595-8
   PubMed Web of Science ®Google Scholar
• Cerezo C, Segura J, Banegas JR, Trends in albuminuria under renin-angiotensin system suppression [abstract]. J Hypertens 2010;28(Suppl A):e446-7
   PubMedGoogle Scholar
• Ontarget Investigators, Yusuf S, Teo KK, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
   PubMed Web of Science ®Google Scholar
• Hoppe UC. Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists? Clin Res Cardiol 2007;96:196-8
   PubMed Web of Science ®Google Scholar
• Nesbitt SD. Antihypertensive combination therapy: optimizing blood pressure control and cardiovascular risk reduction. J Clin Hypertens 2007;9(11 Suppl 4):26-32
   Google Scholar
• Anand IS, Bishu K, Rector TS, Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation 2009;120:1577-84
   PubMed Web of Science ®Google Scholar
• Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006;368:1449-56
   PubMed Web of Science ®Google Scholar
• Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 2008;51:519-28
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, ; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46
   PubMed Web of Science ®Google Scholar
• Solomon SD, Appelbaum E, Manning WJ, Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct Renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119:530-7
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Pitt B, Latini R, ; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24:1663-71
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009;4:542-51
   PubMed Web of Science ®Google Scholar
• de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010;55:147-52
   PubMed Web of Science ®Google Scholar